MDS reports six months net profit of $46.93 million

November 12, 2021

Medical Disposables & Supplies Limited, for the six months ended September 2021 reported Revenue amounting $1.62 billion, an increase of 42%, relative to $1.14 billion booked the previous year. For the second quarter revenues totalled $936.48 million up 49% year over year (2020: $630.16 million). MDS noted, “This increase in sales is due to increased businesss activity as well as the consolidation of the operations of the new subsidiary Cornwall Enterprises Limited. There has been a significant improvement in the movement of pharmaceutical and medical disposable items, especially with fewer lock-down periods when compared to last year.”

Cost of sales went up 38% to close the period at $1.21 billion relative to the $876.81 million reported for the same period last year. This resulted in gross profit which increased 56% to a total of $410.49 million relative to the $263.42 million for the corresponding period in 2020. Gross profit for the second quarter amounted to $234 million, a 55% improvement compared to the $150.59 million reported in 2020.

Total operating expenses closed the period at $310.06 million, up 37% (2020: $226.78 million). Of this, selling and promotional costs went up 14% to $117.38 million (2020: $102.60 million). Administrative expenses increased by 55% to $174.95 million from $112.78 million last year. Depreciation for the first six month amounted to $20.35 million, 45% more than the $13.99 million reported in 2020.

Total operational expenses increased by 61% from $115.95 million recorded in the second quarter of 2020 to $186.45 million in the second quarter of 2021. The company highlighted that the increase, “significantly relates to the consolidation of the subsidiary’s operations.”

Notably, the Company booked other income of $4.75 million for the period ended September 30, 2021 relative to an income of $2.59 million recorded in the same period in 2020.

The Company’s loss on foreign exchange was reported at $5.41 million compared a loss of $76,823 in 2020. Finance cost decreased by 9% to total $45.47 million (2020: $50.14  million). Moreover, Gain on disposal of property, plant and equipment was $50,000 in 2020 (2021: nil). Finance income amounted to $5.11 million (2020: $418,183).

As a result, MDS reported profit before tax of $54.66 million relative to loss before tax of $13.11 million documented in 2020.

Taxation charges amounted to $7.72 million (2020: nil), resulting in a net profit of $46.93 million for the six-month period relative to net loss of $13.11 million in 2020. Net profit for the quarter amounted to $21.45 million (2020: Net loss of $6.04 million).

Earnings per share (EPS) for the period amounted $0.178 (2020: LPS of $0.050). EPS for the quarter amounted to $0.082 relative to LPS of $0.023 in 2020. The trailing twelve-month EPS amounted to $0.49. The number of shares used in the calculations is 263,157,895. MDS last traded on Novembe11, 2021 at $5.60 with a corresponding P/E of 11.37 times.

Balance Sheet Highlights:

As at September 2021, total assets amounted to $2.62 billion 47% more than $1.78 billion booked the year prior. This was primarily due to increases in ‘Property, Plant & Equipment’ and ‘Inventories’ which closed at $800.85 million (2020: 601.07 million) and $943.85 million (2020: $656.04 million), respectively.

Shareholders’ Equity totalled $923.27 million (2020: $820.65 million) resulting in a book value per share of $3.51 (2020: $3.12).


Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation (s) or view (s) expressed by that research analyst in this research report.

Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein